Escape from G1 arrest during acute MEK inhibition drives the acquisition of drug resistance.

Channathodiyil, Prasanna; May, Kieron; Segonds-Pichon, Anne; Smith, Paul D; Cook, Simon J; Houseley, Jonathan

Channathodiyil, Prasanna; May, Kieron; Segonds-Pichon, Anne; Smith, Paul D; Cook, Simon J; Houseley, Jonathan.

Afiliação

Channathodiyil P; Epigenetics Programme, Babraham Institute, Cambridge, CB22 4NT, UK.
May K; Epigenetics Programme, Babraham Institute, Cambridge, CB22 4NT, UK.
Segonds-Pichon A; Babraham Bioinformatics, Babraham Institute, Cambridge, CB22 4NT, UK.
Smith PD; Oncology R&D, AstraZeneca CRUK Cambridge Institute, Cambridge, CB2 0AA, UK.
Cook SJ; Signalling Programme, Babraham Institute, Cambridge, CB22 4NT, UK.
Houseley J; Epigenetics Programme, Babraham Institute, Cambridge, CB22 4NT, UK.

NAR Cancer ; 4(4): zcac032, 2022 Dec.

Article em En | MEDLINE | ID: mdl-36267209

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: NAR Cancer Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google